JP2017505329A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017505329A5 JP2017505329A5 JP2016550633A JP2016550633A JP2017505329A5 JP 2017505329 A5 JP2017505329 A5 JP 2017505329A5 JP 2016550633 A JP2016550633 A JP 2016550633A JP 2016550633 A JP2016550633 A JP 2016550633A JP 2017505329 A5 JP2017505329 A5 JP 2017505329A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- formula
- salt
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 13
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 4
- 210000000845 cartilage Anatomy 0.000 claims 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 3
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 239000011976 maleic acid Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010010356 Congenital anomaly Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 102000014150 Interferons Human genes 0.000 claims 2
- 108010050904 Interferons Proteins 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 230000013632 homeostatic process Effects 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 229940079322 interferon Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 239000000725 suspension Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 238000001816 cooling Methods 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000001035 drying Methods 0.000 claims 1
- 238000001704 evaporation Methods 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 239000012442 inert solvent Substances 0.000 claims 1
- 230000036244 malformation Effects 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1402071.3 | 2014-02-07 | ||
| GBGB1402071.3A GB201402071D0 (en) | 2014-02-07 | 2014-02-07 | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| PCT/EP2015/052242 WO2015117981A1 (en) | 2014-02-07 | 2015-02-04 | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020011555A Division JP2020097595A (ja) | 2014-02-07 | 2020-01-28 | 炎症性障害の治療のための新規な塩及びその医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017505329A JP2017505329A (ja) | 2017-02-16 |
| JP2017505329A5 true JP2017505329A5 (2) | 2018-03-15 |
Family
ID=50390572
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550633A Pending JP2017505329A (ja) | 2014-02-07 | 2015-02-04 | 炎症性障害の治療のための新規な塩及びその医薬組成物 |
| JP2020011555A Pending JP2020097595A (ja) | 2014-02-07 | 2020-01-28 | 炎症性障害の治療のための新規な塩及びその医薬組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020011555A Pending JP2020097595A (ja) | 2014-02-07 | 2020-01-28 | 炎症性障害の治療のための新規な塩及びその医薬組成物 |
Country Status (28)
| Country | Link |
|---|---|
| US (7) | US9382247B2 (2) |
| EP (2) | EP3842432A1 (2) |
| JP (2) | JP2017505329A (2) |
| KR (1) | KR102478614B1 (2) |
| CN (2) | CN105960407A (2) |
| AR (1) | AR099307A1 (2) |
| AU (4) | AU2015215045B2 (2) |
| CA (1) | CA2938219C (2) |
| CY (1) | CY1124349T1 (2) |
| DK (1) | DK3102575T3 (2) |
| EA (2) | EA201990330A1 (2) |
| ES (1) | ES2853375T3 (2) |
| GB (1) | GB201402071D0 (2) |
| HR (1) | HRP20210194T1 (2) |
| HU (1) | HUE053309T2 (2) |
| IL (1) | IL246833B (2) |
| LT (1) | LT3102575T (2) |
| MX (2) | MX395415B (2) |
| NZ (1) | NZ722603A (2) |
| PL (1) | PL3102575T3 (2) |
| PT (1) | PT3102575T (2) |
| RS (1) | RS61450B1 (2) |
| SG (2) | SG10202013187PA (2) |
| SI (1) | SI3102575T1 (2) |
| SM (1) | SMT202100060T1 (2) |
| TW (2) | TWI767878B (2) |
| UY (1) | UY35984A (2) |
| WO (1) | WO2015117981A1 (2) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| GB201402071D0 (en) * | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| GB201402070D0 (en) * | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
| US10376520B2 (en) | 2015-04-13 | 2019-08-13 | Galapagos Nv | Methods for the treatment of cardiovascular disorders |
| MX2017013099A (es) * | 2015-04-13 | 2018-01-26 | Galapagos Nv | Metodos para el tratamiento de trastornos inflamatorios. |
| JP6871919B2 (ja) | 2015-06-16 | 2021-05-19 | ナノファギックス エルエルシー | 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法 |
| CN105198878B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物f晶型及其制备方法 |
| CN105111206B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物e晶型及其制备方法 |
| CN105198879B (zh) * | 2015-09-18 | 2017-09-22 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物c晶型及其制备方法 |
| CN105198876B (zh) * | 2015-09-18 | 2017-09-29 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物h晶型及其制备方法 |
| CN105198877B (zh) * | 2015-09-18 | 2017-09-22 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物g晶型及其制备方法 |
| CN105218539B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物b晶型及其制备方法 |
| CN105198880B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物a晶型及其制备方法 |
| CN105111207B (zh) * | 2015-09-18 | 2017-07-25 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物d晶型及其制备方法 |
| US20170173034A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders |
| WO2017106568A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and a bromodomain inhibitor for treating cancer |
| WO2017106566A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders |
| CN105669669A (zh) * | 2016-03-04 | 2016-06-15 | 上海宣创生物科技有限公司 | 一种环丙烷甲酰胺衍生物的a晶型、b晶型、d晶型、g晶型和m晶型及其制备方法 |
| CA3018610A1 (en) * | 2016-03-21 | 2017-09-28 | Crystal Pharmatech Co., Ltd | Crystalline forms of hydrochloride of drug for treating or preventing jak-associated disease and preparation method thereof |
| WO2018024236A1 (zh) * | 2016-08-03 | 2018-02-08 | 苏州科睿思制药有限公司 | 一种jak1选择性抑制剂的新晶型及其制备方法和用途 |
| AU2017358703A1 (en) | 2016-11-10 | 2019-05-09 | Galapagos Nv | Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases |
| GB201702603D0 (en) | 2017-02-17 | 2017-04-05 | Galápagos Nv | Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| HRP20240112T1 (hr) * | 2017-03-14 | 2024-04-12 | Galapagos Nv | Farmaceutske tvari koje uključuju inhibitor janus kinaze (jak) |
| GB201808575D0 (en) | 2018-05-24 | 2018-07-11 | Galapagos Nv | Methods for the treatment of psoriatic arthrits |
| US10815227B2 (en) | 2018-08-27 | 2020-10-27 | Cadila Healthcare Limited | Processes for the preparation of filgotinib |
| WO2020092245A1 (en) * | 2018-10-29 | 2020-05-07 | Zorday IP, LLC | Network-enabled electronic cigarette |
| WO2020177705A1 (zh) * | 2019-03-05 | 2020-09-10 | 苏州科睿思制药有限公司 | Filgotinib的马来酸盐晶型CSI及其制备方法和用途 |
| BR112021019087A2 (pt) * | 2019-03-30 | 2021-11-30 | Unichem Lab Ltd | Novo processo para a preparação de filgotinibe e intermediários do mesmo |
| WO2021044327A1 (en) * | 2019-09-03 | 2021-03-11 | Dr. Reddy's Laboratories Limited | Solid forms of filgotinib maleate and processes thereof |
| CN114075188A (zh) * | 2020-08-11 | 2022-02-22 | 南京柯菲平盛辉制药有限公司 | 芳香杂环酰胺类化合物及其制备方法和医药用途 |
| US20240033309A1 (en) * | 2020-12-09 | 2024-02-01 | Servatus Ltd | Combination therapy for inflammatory disorders of the joints |
| CN113773322B (zh) * | 2021-11-10 | 2022-02-11 | 奥锐特药业(天津)有限公司 | 一种Filgotinib的制备方法 |
| WO2026027676A1 (en) | 2024-07-31 | 2026-02-05 | Alfasigma S.P.A. | Biomarkers for determining treatment of ulcerative colitis with filgotinib |
| WO2026027669A1 (en) | 2024-07-31 | 2026-02-05 | Alfasigma S.P.A. | Biomarkers for determining treatment of ulcerative colitis with filgotinib |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2549632B2 (ja) * | 1986-08-20 | 1996-10-30 | 三井石油化学工業株式会社 | オレフインの重合方法 |
| EP1156037B1 (en) | 1999-01-29 | 2004-12-01 | Chugai Seiyaku Kabushiki Kaisha | Chondrongenesis promotors and indolin-2-one derivatives |
| JPWO2002087620A1 (ja) | 2001-04-27 | 2004-08-12 | 中外製薬株式会社 | 軟骨形成促進剤 |
| US6514989B1 (en) | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
| AU2003275682A1 (en) * | 2002-10-29 | 2004-05-25 | Shionogi And Co., Ltd. | Crystal of inorganic acid salt of cephem compound |
| EP1601672B1 (en) | 2003-02-14 | 2006-07-26 | Pfizer Products Inc. | Triazolo-pyridines as anti-inflammatory compounds |
| US20050222171A1 (en) | 2004-01-22 | 2005-10-06 | Guido Bold | Organic compounds |
| JP2008503712A (ja) | 2004-06-21 | 2008-02-07 | ガラパゴス・ナムローゼ・フェンノートシャップ | 骨関節炎治療の方法及び手段 |
| US20090209577A1 (en) | 2004-08-18 | 2009-08-20 | Pfizer Inc. | Novel Triazolopyridine Compounds |
| EP1799680A2 (en) | 2004-10-07 | 2007-06-27 | Warner-Lambert Company LLC | Triazolopyridine derivatives as antibacterial agents |
| GB0515026D0 (en) | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
| BRPI0716239A2 (pt) | 2006-08-30 | 2013-08-13 | Cellzome Ltd | derivados de triazol como inibidores de cinase |
| CL2008001626A1 (es) | 2007-06-05 | 2009-06-05 | Takeda Pharmaceuticals Co | Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer. |
| CA2693232A1 (en) | 2007-07-18 | 2009-01-22 | Novartis Ag | Bicyclic heteroaryl compounds and their use as kinase inhibitors |
| WO2009017954A1 (en) * | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
| CA2691448A1 (en) | 2007-08-31 | 2009-03-05 | Dominique Swinnen | Triazolopyridine compounds and their use as ask inhibitors |
| GB0719803D0 (en) | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| WO2009155565A1 (en) | 2008-06-20 | 2009-12-23 | Genentech, Inc. | Triazolopyridine jak inhibitor compounds and methods |
| WO2010010188A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
| WO2010010189A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2010010187A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| JO3041B1 (ar) * | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
| WO2010010186A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2010010184A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors |
| JPWO2010013768A1 (ja) * | 2008-07-31 | 2012-01-12 | 第一三共株式会社 | チアゾリジンジオン化合物の結晶及びその製造方法 |
| EP2438066A2 (en) | 2009-06-05 | 2012-04-11 | Cephalon, Inc. | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a]PYRIDINE DERIVATIVES |
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| JO3030B1 (ar) | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
| WO2011036895A1 (ja) * | 2009-09-25 | 2011-03-31 | 杏林製薬株式会社 | マレイン酸塩およびその結晶 |
| CN102146082A (zh) * | 2010-02-04 | 2011-08-10 | 江苏恒瑞医药股份有限公司 | 吡咯并n杂环类衍生物的可药用的盐、其制备方法及其在医药上的应用 |
| JP2013049632A (ja) * | 2011-08-30 | 2013-03-14 | Kowa Co | ベンゾチアジン化合物のモノマレイン酸塩を有効成分とするアレルギー疾患の予防及び／又は治療剤 |
| SA112330992B1 (ar) * | 2011-11-10 | 2015-09-13 | كيورين فارماسوتيكال كو.، ليمتد | صورة متبلرة من 7-{(s4، s3)-3-[(سيكلو بروبيل أمينو) ميثيل]-4-فلورو بيروليدين-1-يل}-6-فلورو-1-(2-فلورو إيثيل)- 8-ميثوكسي-4-أوكسو-1، 4-داي هيدرو كينولين-3- حمض كربوكسيلي |
| WO2013173506A2 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
| US9284311B2 (en) * | 2012-06-22 | 2016-03-15 | Galapagos Nv | Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof |
| GB201402070D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
| GB201402071D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| US10376520B2 (en) | 2015-04-13 | 2019-08-13 | Galapagos Nv | Methods for the treatment of cardiovascular disorders |
| MX2017013099A (es) | 2015-04-13 | 2018-01-26 | Galapagos Nv | Metodos para el tratamiento de trastornos inflamatorios. |
| US20170173034A1 (en) | 2015-12-17 | 2017-06-22 | Gilead Sciences, Inc. | Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders |
| HRP20240112T1 (hr) | 2017-03-14 | 2024-04-12 | Galapagos Nv | Farmaceutske tvari koje uključuju inhibitor janus kinaze (jak) |
| GB201808575D0 (en) | 2018-05-24 | 2018-07-11 | Galapagos Nv | Methods for the treatment of psoriatic arthrits |
-
2014
- 2014-02-07 GB GBGB1402071.3A patent/GB201402071D0/en not_active Ceased
-
2015
- 2015-02-04 WO PCT/EP2015/052242 patent/WO2015117981A1/en not_active Ceased
- 2015-02-04 RS RS20210134A patent/RS61450B1/sr unknown
- 2015-02-04 EA EA201990330A patent/EA201990330A1/ru unknown
- 2015-02-04 CA CA2938219A patent/CA2938219C/en active Active
- 2015-02-04 EP EP20211405.4A patent/EP3842432A1/en not_active Withdrawn
- 2015-02-04 CN CN201580006893.3A patent/CN105960407A/zh active Pending
- 2015-02-04 LT LTEP15704974.3T patent/LT3102575T/lt unknown
- 2015-02-04 SG SG10202013187PA patent/SG10202013187PA/en unknown
- 2015-02-04 MX MX2020003368A patent/MX395415B/es unknown
- 2015-02-04 US US14/614,396 patent/US9382247B2/en active Active
- 2015-02-04 AU AU2015215045A patent/AU2015215045B2/en active Active
- 2015-02-04 PT PT157049743T patent/PT3102575T/pt unknown
- 2015-02-04 EP EP15704974.3A patent/EP3102575B1/en active Active
- 2015-02-04 JP JP2016550633A patent/JP2017505329A/ja active Pending
- 2015-02-04 ES ES15704974T patent/ES2853375T3/es active Active
- 2015-02-04 MX MX2016010068A patent/MX376000B/es active IP Right Grant
- 2015-02-04 DK DK15704974.3T patent/DK3102575T3/da active
- 2015-02-04 PL PL15704974T patent/PL3102575T3/pl unknown
- 2015-02-04 KR KR1020167023807A patent/KR102478614B1/ko active Active
- 2015-02-04 CN CN202010324636.7A patent/CN111499630A/zh active Pending
- 2015-02-04 HR HRP20210194TT patent/HRP20210194T1/hr unknown
- 2015-02-04 EA EA201691584A patent/EA032596B1/ru unknown
- 2015-02-04 SG SG11201606433PA patent/SG11201606433PA/en unknown
- 2015-02-04 HU HUE15704974A patent/HUE053309T2/hu unknown
- 2015-02-04 IL IL246833A patent/IL246833B/en unknown
- 2015-02-04 SM SM20210060T patent/SMT202100060T1/it unknown
- 2015-02-04 SI SI201531491T patent/SI3102575T1/sl unknown
- 2015-02-04 NZ NZ722603A patent/NZ722603A/en unknown
- 2015-02-06 TW TW104104160A patent/TWI767878B/zh active
- 2015-02-06 UY UY0001035984A patent/UY35984A/es not_active Application Discontinuation
- 2015-02-06 AR ARP150100351A patent/AR099307A1/es unknown
- 2015-02-06 TW TW110136599A patent/TWI792593B/zh active
-
2016
- 2016-07-01 US US15/200,228 patent/US20160376269A1/en not_active Abandoned
-
2017
- 2017-07-10 US US15/645,308 patent/US10708263B2/en active Active
-
2019
- 2019-04-08 AU AU2019202441A patent/AU2019202441B2/en active Active
- 2019-09-30 US US16/588,207 patent/US10919890B2/en active Active
-
2020
- 2020-01-28 JP JP2020011555A patent/JP2020097595A/ja active Pending
- 2020-10-26 AU AU2020260391A patent/AU2020260391B2/en active Active
-
2021
- 2021-01-08 US US17/144,788 patent/US11667633B2/en active Active
- 2021-02-01 CY CY20211100080T patent/CY1124349T1/el unknown
-
2022
- 2022-09-23 AU AU2022235624A patent/AU2022235624B2/en active Active
-
2023
- 2023-04-25 US US18/306,867 patent/US12234235B2/en active Active
-
2025
- 2025-01-22 US US19/033,986 patent/US20250289816A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017505329A5 (2) | ||
| CN101679218B (zh) | 晶体米诺环素碱及其制备方法 | |
| TW201630901A (zh) | 製備ａｓｋ１抑制劑之方法 | |
| JP2019504103A5 (2) | ||
| RU2613555C2 (ru) | Моногидратный кристалл калиевой соли фимасартана, способ его получения и содержащая его фармакологическая композиция | |
| CN107427503A (zh) | 2‑(5‑(3‑氟苯基)‑3‑羟基吡啶甲酰胺)乙酸的固体形式、其组合物及用途 | |
| JP2011512396A (ja) | 新規な多形およびその調製方法 | |
| JP2019505532A5 (2) | ||
| JP2007520546A (ja) | モンテルカストナトリウムの安定な非晶質性形態 | |
| CN104098548B (zh) | 一种Delafloxacin的精制方法 | |
| CN107698574B (zh) | 一种高纯度阿瑞匹坦的精制制备工艺 | |
| CN107033094A (zh) | 一种药物共晶的晶型及其制备方法和组合物 | |
| CN103936717A (zh) | 一种delafloxacin中间体及其制备方法 | |
| CN105440019A (zh) | 一种治疗胃酸疾病药物的制备方法 | |
| CN111718329A (zh) | 一种德拉沙星杂质iv及产品精制方法 | |
| CN107586288A (zh) | 一种富马酸沃诺拉赞的纯化方法 | |
| CN105646446A (zh) | 一种纯化阿格列汀的方法 | |
| CN103965163A (zh) | 一种含嘧啶环的喹诺酮类衍生物及其制备方法和用途 | |
| CN104703967A (zh) | 氟伏沙明游离碱的精制方法及利用其的高纯度马来酸氟伏沙明的制备方法 | |
| JP2013184902A5 (ja) | リファキシミン結晶 | |
| WO2005103048A1 (en) | Quinolone carboxylic acid derivatives, thereof preparation and usage | |
| WO2019207602A1 (en) | Polymorphic forms of bictegravir and its sodium salt | |
| JP2024546098A5 (2) | ||
| CN109790172B (zh) | 纳曲酮的分离和纯化方法 | |
| CN107739328B (zh) | 用于合成巴瑞替尼的关键中间体1的制备方法 |